fam-trastuzumab deruxtecan-nxki for injection
for intravenous use Initial U.S. Approval: 2019
fam-trastuzumab deruxtecan-nxki for Injection is a “used to treat Metastatic Breast Cancer and Locally Advanced or Metastatic Gastric Cancer“. ENHERTU for injection is a “prescription medicine. It is available in “form and strength” For injection: 100 mg lyophilized powder in a single-dose vial. ENHERTU for injection can be obtained in India upon request.
To inquire about the “offer price in India”, “shipping process”, and the “estimated time of availability in India”, please get in touch at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj). with the IPN Delhi healthcare team for further discussion.”
Facts about your medicine
Name: ENHERTU
Active fam-trastuzumab deruxtecan-nxki
Approval Date:2019
Proprietary Name: On Request
Active Ingredient(s): fam-trastuzumab deruxtecan-nxki
Dosage Forms And Strengths: For injection: 100 mg lyophilized powder in a single-dose via
Manufacturer:
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)